For all cataract surgeons managing glaucoma patients
The world’s first, IOL-mounted, controlled release drug delivery platform capable of delivering multiple years of therapy
CONSISTENT DAILY RELEASE
Targeting 3-year delivery of bimatoprost to treat glaucoma in patients undergoing cataract surgery
Dual pads securely attached to each haptic are designed to elute treatment continuously for multiple years.
The SpyGlass Drug Delivery Platform has not been approved by FDA for any use
Directly addressing an unmet need
Patient non-adherence to their glaucoma medication can lead to complications, disease progression and vision loss. Methods of drug delivery independent of patient behavior is an industry-wide need.
Millions of glaucoma patients undergo cataract surgery each year
Intraocular drug delivery that lasts
Learn more about SpyGlass Pharma
SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases
SpyGlass Pharma, a privately-held ophthalmic therapeutics company, announced today closing $90 million in Series C financing. The financing, which was led by RA Capital Management alongside existing investors New Enterprise Associates (“NEA”) and Vensana Capital, as well as new investors Samsara BioCapital and Vertex Ventures HC, will enable the company to conduct multiple US clinical trials of SpyGlass’ innovative drug delivery platform. (View full press release)